106 related articles for article (PubMed ID: 28207300)
1. Single Nucleotide rs760370 Polymorphism at the Main Ribavirin Transporter Gene Detection by PCR-RFLP Assay Compared with the TaqMan Assay and Its Relation to Sustained Virological Response in Chronic HCV Patients Treated with Pegylated Interferon-Ribavirin Therapy.
Fouad R; Zachariah K; Khairy M; Khorshied M; Ezzat W; Sheta MM; Heiba A
J Interferon Cytokine Res; 2017 Feb; 37(2):90-96. PubMed ID: 28207300
[TBL] [Abstract][Full Text] [Related]
2. Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection.
Morello J; Cuenca L; Soriano V; Medrano J; Madejón A; Vispo E; Barreiro P; Labarga P; Jiménez-Nácher I; Rodríguez-Nóvoa S
J Infect Dis; 2010 Oct; 202(8):1185-91. PubMed ID: 20812847
[TBL] [Abstract][Full Text] [Related]
3. SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir.
Milazzo L; Peri AM; Mazzali C; Magni C; Calvi E; De Nicolò A; Clementi E; Cheli S; D'Avolio A; Antinori S; Falvella FS
J Antimicrob Chemother; 2015 Apr; 70(4):1155-60. PubMed ID: 25583751
[TBL] [Abstract][Full Text] [Related]
4. Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients.
Tsubota A; Shimada N; Yoshizawa K; Furihata T; Agata R; Yumoto Y; Abe H; Ika M; Namiki Y; Chiba K; Fujise K; Tada N; Aizawa Y
Liver Int; 2012 May; 32(5):826-36. PubMed ID: 22212648
[TBL] [Abstract][Full Text] [Related]
5. Sustained viral response and treatment-induced cytopenia correlate with SLCs and KLF12 genotypes in interferon/ribavirin-treated Chinese chronic hepatitis C patients.
Mei R; Chi X; Wu R; Xu H; Wang X; Gao X; Sun H; Lv J; Yu G; Kong F; Jiang J; Sun B; Zhong J; Pan Y; Niu J
J Gastroenterol Hepatol; 2016 Aug; 31(8):1489-97. PubMed ID: 26750805
[TBL] [Abstract][Full Text] [Related]
6. Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C.
Doehring A; Hofmann WP; Schlecker C; Zeuzem S; Sarrazin C; Berg T; Müller T; Herrmann E; Geisslinger G; Lötsch J
Pharmacogenet Genomics; 2011 May; 21(5):289-96. PubMed ID: 21346688
[TBL] [Abstract][Full Text] [Related]
7. Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated-interferon and ribavirin.
Su PY; Yen HH; Hsu YC; Wu SS; Kor CT; Su WW
Kaohsiung J Med Sci; 2016 Jul; 32(7):381-6. PubMed ID: 27450028
[TBL] [Abstract][Full Text] [Related]
8. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
[TBL] [Abstract][Full Text] [Related]
9. Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon α Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection.
Ali FT; Ali MA; Elgizawy MM; Elsawy AM
Gut Liver; 2015 Jul; 9(4):516-24. PubMed ID: 25717047
[TBL] [Abstract][Full Text] [Related]
10. Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients.
Baleriola C; Rawlinson WD; Dore GJ; Chaverot S; Stelzer-Braid S; Yoshihara M; Crawford D; Sievert W; McCaughan G; Weltman M; Cheng W; Rizkalla B; Dubois D; Thommes J; Roberts S
Antivir Ther; 2011; 16(2):173-80. PubMed ID: 21447866
[TBL] [Abstract][Full Text] [Related]
11. Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.
Namikawa M; Kakizaki S; Yata Y; Yamazaki Y; Horiguchi N; Sato K; Takagi H; Mori M
J Gastroenterol Hepatol; 2012 Jan; 27(1):69-75. PubMed ID: 21649727
[TBL] [Abstract][Full Text] [Related]
12. [Predicting sustained virological response in chronic hepatitis C patients treated with pegylated interferon and ribavirin using a novel highly sensitive Real-time detection PCR assay].
Matsuura K; Tanaka Y; Takagi K; Hiramatsu K; Kani S; Gotoh T; Wakimoto Y; Joh T; Mizokami M
Rinsho Byori; 2007 Nov; 55(11):983-8. PubMed ID: 18154028
[TBL] [Abstract][Full Text] [Related]
13. Impact of the IL-18 gene polymorphism in response to antiviral therapy in chronic HCV genotype 4 patients.
Mandour M; Nemr N; Kishk R; Ahmed E
Rev Soc Bras Med Trop; 2014; 47(2):137-42. PubMed ID: 24861285
[TBL] [Abstract][Full Text] [Related]
14. Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients.
Allegra S; Cusato J; De Nicolò A; Boglione L; Gatto A; Cariti G; Di Perri G; D'Avolio A
Biomed Pharmacother; 2015 Feb; 69():47-55. PubMed ID: 25661337
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
16. Gene polymorphisms of IL-10 and MxA in responders and non-responders to interferon therapy in HCV Egyptian patients genotype 4.
Shaker OG; Abdel-Rahim MT; Bayoumi ST
Cell Biochem Biophys; 2015 Mar; 71(2):617-25. PubMed ID: 25239021
[TBL] [Abstract][Full Text] [Related]
17. Effect of IL15 rs10833 and SCARB1 rs10846744 on virologic responses in chronic hepatitis C patients treated with pegylated interferon-α and ribavirin.
Sadeghi S; Davari M; Asli E; Gharibzadeh S; Vaziri F; Jamnani FR; Fateh A; Siadat SD
Gene; 2017 Sep; 630():28-34. PubMed ID: 28827115
[TBL] [Abstract][Full Text] [Related]
18. Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C.
Sanjo M; Saito T; Ishii R; Nishise Y; Haga H; Okumoto K; Ito J; Watanabe H; Saito K; Togashi H; Fukuda K; Imai Y; El-Shamy A; Deng L; Shoji I; Hotta H; Kawata S
J Med Virol; 2010 Aug; 82(8):1364-70. PubMed ID: 20572079
[TBL] [Abstract][Full Text] [Related]
19. Correlation of OAS1 gene polymorphism at exon 7 splice accepter site with interferon-based therapy of HCV infection in Pakistan.
Imran M; Manzoor S; Khattak NM; Tariq M; Khalid M; Javed F; Bhatti S
Viral Immunol; 2014 Apr; 27(3):105-11. PubMed ID: 24673406
[TBL] [Abstract][Full Text] [Related]
20. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
